Skip to content
Health & Medical

Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India


Sai Life Sciences, one of India’s fastest growing global Contract Research, Development & Manufacturing Organisations [ ] (CRO-CDMO), today announced that it has entered a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up the Sai Schrödinger Research Laboratories (SSRL) in Hyderabad, India.

Being built inside Sai Life Sciences’ R&D campus in genome valley, Hyderabad, SSRL will be a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry [ ], in vitro biology [ ], and process chemistry [ ]. It will access other Sai capabilities such as in vitro ADME [ ] and in vivo PK [ ] as needed. The relationship will support advancement of programs that leverage Schrödinger’s validated computational platform.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “We’re truly delighted that Schrödinger has decided to partner with Sai Life Sciences to set-up their first offshore research laboratories. In many ways, this is a testimony to the advances we have made in the scale, scope and depth of our integrated drug discovery [ ] capabilities. We are very excited about working with the Schrödinger team and, guided by our brand promise, will strive to make it better together.”

Scheduled to open in April 2023, SSRL will commence with about 75 staff members, across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry, Analytical Chemistry, and other support staff. Recruitment has commenced for SSRL, and the open positions can be viewed here [ ].

The Discovery business [ ] of Sai Life Sciences has been witnessing a transformative phase of growth in recent years, as is evidenced in its expanding client mix and diversity of programs. Powered by investments in talent, technology and capacity across Boston and Hyderabad, the company’s global delivery model is delivering unique value to its customers through an optimal blend of talent, speed, and cost efficiency. This journey typically starts with its exploratory biology facility [ ] in Boston, where the company works hand-in-hand with clients in real-time on early discovery biology programs that are difficult to outsource. These programs then transition to the company’s Hyderabad R&D campus [ ], where it has consolidated its chemistry, biology and ADME-PK services in one integrated campus, allowing Sai scientists to work as teams and deliver quality data to its customers.

About Sai Life Sciences

Sai Life Sciences is a full-service CRO-CDMO [ ] that works with innovator pharma and biotech companies globally, to accelerate the discovery, development and commercialisation of small molecules. It takes a nimble and creative approach to deliver high-quality, cost-effective solutions for its clients that accelerate their time to market. Backed by global investors, TPG Capital and HBM Healthcare Investments, the company today works with over 200 innovator companies globally and has over 2500 employees across its facilities in India, UK and USA.



Source: Sai Life Sciences